Comparable stake leader
Yong Chan Kim
SEC ownership of Baudax Bio, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001780097.
Disclosed value leader
Yong Chan Kim
Comparable rows
0/9
Latest evidence
03 Jul 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Yong Chan Kim
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
03 Jul 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001780097
- Issuer location
- Malvern, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Baudax Bio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Yong Chan Kim
Disclosed value leader
Yong Chan Kim
Comparable rows
0/9
Latest evidence
03 Jul 2023
3/4/5
Highest disclosed value: $515,278
9 rows are not safely comparable across share classes.
Showing 1-8 of 9 holder rows.
Quick read
Yong Chan Kim has the largest disclosed position value at $515.3K.
0 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Yong Chan Kim's linked filing trail.
Disclosed position value
Top 5
Yong Chan Kim
$515.3K
Richard S. Casten
$509.5K
Winston J. Churchill
$119.3K
Wayne Weisman
$109.3K
William L. Ashton
$108.4K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Yong Chan Kim |
3/4/5
Director
|
—
class O/S missing
|
$515,278
202,260 shares
|
— | 03 Jul 2023 |
| Richard S. Casten |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
$509,520
200,000 shares
|
— | 20 Aug 2021 |
| Winston J. Churchill |
3/4/5
Director
|
—
class O/S missing
|
$119,279
46,820 shares
|
— | 15 Jun 2022 |
| Wayne Weisman |
3/4/5
Director
|
—
class O/S missing
|
$109,292
42,900 shares
|
— | 15 Jun 2022 |
| William L. Ashton |
3/4/5
Director
|
—
class O/S missing
|
$108,360
42,534 shares
|
— | 15 Jun 2022 |
| Arnold M. Baskies |
3/4/5
Director
|
—
class O/S missing
|
$106,851
41,942 shares
|
— | 15 Jun 2022 |
| Drechsler Andrew T. |
3/4/5
Director
|
—
class O/S missing
|
$106,123
41,656 shares
|
— | 15 Jun 2022 |
| Jillian Dilmore |
3/4/5
Corporate Controller/Secretary, PFO and PAO
|
—
class O/S missing
|
$40,094
15,738 shares
|
— | 15 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 22 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to Baudax Bio, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Yong Chan Kim
Net 12M change
$0
Latest report
09 Oct 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Yong Chan Kim | Director | $515,278 | Mixed | 03 Jul 2023 | ||
| Richard S. Casten | Chief Financial Officer | $509,520 | Mixed | 20 Aug 2021 | ||
| Winston J. Churchill | Director | $119,279 | Mixed | 15 Jun 2022 | ||
| Wayne Weisman | Director | $109,292 | Mixed | 15 Jun 2022 | ||
| William L. Ashton | Director | $108,360 | Mixed | 15 Jun 2022 | ||
| Arnold M. Baskies | Director | $106,851 | Mixed | 15 Jun 2022 | ||
| Drechsler Andrew T. | Director | $106,123 | Mixed | 15 Jun 2022 | ||
| Jillian Dilmore | Corporate Controller/Secretary, PFO and PAO | $40,094 | Mixed | 15 Jun 2022 | ||
| Geraldine Henwood | President and CEO, Director | $6,219 | Mixed | 15 Dec 2022 | ||
| Natalie McAndrew | Interim CFO | Mixed | 09 Oct 2023 |
Recent insider transactions for Baudax Bio, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.